drugset / Trial / NCT00738049

Darusentan Effect on PET Uptake Heterogeneity

NCT00738049

Phase 2 Completed 40 enrolled K.Lance Gould Gilead Sciences · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.

Timeline

Start
2009-06
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darusentan Other / unclassified 100 mg Oral